Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
First Appeared on 4/14/2016
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|HPV4: HPV (GARDASIL) / MERCK & CO. INC.||- / 1||UN / UN|
Administered by: Other Purchased by: Other
Symptoms: Aphasia, Optic neuritis, Seizure, Visual impairment, Noninfective encephalitis
Life Threatening? No
Permanent Disability? Yes
ER or Doctor Visit? Yes
Other Medications: No other medications
Current Illness: Unknown
Diagnostic Lab Data:
CDC 'Split Type': WAES1603USA014305
Write-up:This spontaneous report as received from a pharmacist (patient''s father) via company field representative refers to a 12 years old female patient. The patient''s medical history and concurrent conditions were none. On an unspecified date in July-2015 the patient had received her second dose of GARDASIL, lot # and expiry date was not reported. The patient had received unspecified concomitant medications. On an unspecified date in July-2015, the patient experienced visual disturbances (disability) and optic neuritis (disability). Therapy with GARDASIL was discontinued on an unspecified date in July-2015. Later in December-2015, she had chronic seizures (disability). Recently, on an unspecified date, she was diagnosed with inflammation of the left hemisphere of her brain (disability) and she could not speak (disability). The GARDASIL was not reintroduced. The outcome of the events were reported as not recovered. Upon internal review the events cannot speak, chronic seizures and inflammation of the left hemisphere of her brain were considered to be medically significant. Additional information has been requested.
Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166